|01/03/17||Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 3 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.
The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors & Media section.
About Global Blood The... |
|12/16/16||Global Blood Therapeutics Added to NASDAQ Biotechnology Index|
|SOUTH SAN FRANCISCO, Calif., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI). GBT’s addition to the NBI will become effective upon market open on Monday, December 19, 2016.
The NASDAQ Biotechnology Index, which is re-ranked annually, is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or ... |
|12/05/16||Global Blood Therapeutics Announces New Details on its Novel Patient Reported Outcomes (PRO) Tool to be used in Phase 3 HOPE Study|
|-- PRO designed to establish clinical benefit –
-- First time a PRO to be used as a secondary clinical endpoint in a SCD registrational study --
--Company to Host Webcast Today at 12:15 p.m. PT to Discuss ASH Data Presentations —
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the methodology used to develop the Patient Reported Outcome (PRO) tool that will be used as a secondary clinical endpoint in th... |
|12/04/16||Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH|
|--Results Showed GBT440 Treatment Led to Rapid, Significant, Profound and Durable Reduction in Hemolysis and Sickled Cells in All Patients Treated for Up to Six Months--
--Company to Host Webcast Tomorrow at 12:15 p.m. PT to Discuss Data--
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile o... |